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Purpose: Here we assessed associations between null mutations in glutathione-S-transferase (GST)T1 and GSTM1
genes, and the rs1695 polymorphism in GSTP1 (Ile105Val), and risk of breast cancer-specific (n=45) and all-cause
(n=99) mortality in a multiethnic, prospective cohort of 533 women diagnosed with stage I-IIIA breast cancer in
1995–1999, enrolled in the Health, Eating, Activity, and Lifestyle (HEAL) Study.
Methods: We measured the presence of the null mutation in GSTT1 and GSTM1, and the rs1695 polymorphism in
GSTP1 by polymerase chain reaction. We assessed associations between breast-cancer specific and all-cause
mortality using Cox proportional hazards models.
Results: Participants with ER-negative tumors were more likely to be GSTT1 null (χ2=4.52; P=0.03), and African
American women were more likely to be GSTM1 null (χ2=34.36; P<0.0001). Neither GSTM1 nor GSTT1 null mutations
were associated with breast cancer-specific or all-cause mortality. In a model adjusted for body mass index,
race/ethnicity, tumor stage and treatment received at diagnosis, the variant Val allele of rs1695 was associated with
increased risk of all-cause (HR=1.81, 95% CI 1.16-2.82, P=0.008), but not breast cancer-specific mortality. The GSTT1 null
mutation was associated with significantly higher levels of C-reactive protein.
Conclusions: GSTM1 and GSTT1 null genotypes had no effect on outcome; however the variant allele of rs1695 appears
to confer increased risk for all-cause mortality in breast-cancer survivors.
Given the limited sample size of most studies examining associations between GST polymorphisms with breast cancer
survival, and the lack of women undergoing more contemporary treatment protocols (treated prior to 1999), it may be
helpful to re-examine this issue among larger samples of women diagnosed after the late 1990s, who all received some
form of chemotherapy or radiotherapy.
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The Glutathione-S Transferases (GST) are a phase II
superfamily of cytosolic, mitochondrial and microsomal
enzymes that catalyze the conjugation of reduced glutathi-
one to electrophilic centers on a variety of substrates
(Strange et al. 2001). This activity is acts a detoxification
step for a variety of endogenous molecules and xenobi-
otics, including chemotherapeutic drugs. The mammalian* Correspondence: cduggan@fhcrc.org
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alpha (α), mu (μ), pi (π), theta (τ), zeta (ζ) and omega (ω).
GST-μ, GST-τ, and GST-π are encoded by the GSTM1,
GSTT1, and GSTP1 genes, respectively; and these 3 genes
have been studied in association with genetic susceptibility
to cancer (Strange & Fryer 1999; Spurdle et al. 2010).
Homozygous deletion of the GSTM1 and GSTT1 genes
(null genotype), are associated with a lack of enzyme func-
tion and increased vulnerability to cytogenetic damage
(Seidegard et al. 1988). Individuals who have deletions in
GSTM1 or GSTT1 may therefore be at increased cancer
risk (Strange & Fryer 1999; Rebbeck 1997).an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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tion at position 313) results in an Ile→Val change at codon
105 (Ile105Val). The variant allele is associated with lower
substrate-specific catalytic activity, including towards the
alkylating anticancer agent chlorambucil (Hayes & Strange
2000; Pandya et al. 2000; Srivastava et al. 1999). A limited
number of studies with conflicting results have investigated
the association between polymorphisms in GST genes
and mortality in breast cancer patients. The majority of
these studied patients diagnosed prior to 1999. Five of
six studies have samples of women undergoing chemo-
therapy and/or radiotherapy, and most examined only one
GST gene (usually GSTP1). Four of the six (Ambrosone
et al. 2001; Bewick et al. 2008; Lizard-Nacol et al. 1999;
Sweeney et al. 2000) were based on small samples of pa-
tients (N<100; (Bewick et al. 2008; Lizard-Nacol et al.
1999) N=240-250 (Ambrosone et al. 2001; Sweeney et al.
2000)). One large study of 2430 breast cancer patients was
comprised of women with early stage disease (94%) who
were unlikely to have undergone chemotherapy, (Goode
et al. 2002) and found no association with the only GST
examined (GSTP1) and survival. One other large study of
1034 women from Shanghai, China, all treated with adju-
vant chemotherapy, found a reduction in risk with the vari-
ant GSTP1 Val allele but no association with either GSTT1
or GSTM1 and risk of death (Yang et al. 2005). In two
reports based on the same sample, women with breast
cancer with null mutations for GSTM1 and GSTT1 had
reduced risk of death compared to women with alleles
present, (Ambrosone et al. 2001) and a reduction in
mortality risk for women homozygous for the variant
GSTP1 Val allele compared to those homozygous for
the Ile allele (Sweeney et al. 2000; Yang et al. 2005). Fi-
nally, 2 other small studies examined associations be-
tween one GST polymorphism among women treated
with high dose chemotherapy, one reported no associ-
ation between survival and GSTM1 null; (Lizard-Nacol
et al. 1999) another, that the GSTP1 Val/Val polymorph-
ism was non-significantly associated with worse overall
survival (Bewick et al. 2008).
Two studies (one in smokers, and the other in patients
with diabetes), reported an association between GSTT1
and GSTM1 null mutations and lower levels of the in-
flammatory biomarker CRP, (Hayek et al. 2006; Miller
et al. 2003) itself associated with poor survival (Pierce
et al. 2009a). We thus examined this association in the
Health, Eating, Activity and Lifestyle (HEAL) study.
We extend prior research by examining the association
between three different GST isoenzymes (null mutations
in GSTM1 and GSTT1, the Ile105Val polymorphism in
GSTP1), and all-cause and breast-cancer specific mortality
in a multi-ethnic cohort of breast cancer survivors drawn
from population-based cancer registries. This sample
of breast cancer patients diagnosed from 1995–1999includes a larger number of women undergoing chemo-
therapy and/or radiotherapy than most prior studies
(Ambrosone et al. 2001; Bewick et al. 2008; Lizard-Nacol
et al. 1999; Sweeney et al. 2000) and reflects more contem-
porary therapy regimens than those based on women
treated in the mid-1980s-mid-1990s (Ambrosone et al.
2001; Bewick et al. 2008; Lizard-Nacol et al. 1999; Sweeney
et al. 2000).
Materials and methods
Study setting, participants, and recruitment
The HEAL Study is a multicenter, multiethnic prospect-
ive cohort study which enrolled 1,183 women diagnosed
with breast cancer, to evaluate effects of diet, weight,
physical activity, lifestyle, hormones or other exposures
on breast-cancer prognosis. Aims, study design and re-
cruitment procedures have been published previously
(McTiernan et al. 2003).
Briefly, women were recruited through Surveillance,
Epidemiology, and End Results (SEER) registries in New
Mexico (NM), Los Angeles County (CA), and western
Washington (WA). Baseline surveys were conducted on
average 6-months post-diagnosis. In NM, we recruited
615 women, ≥18 years, diagnosed with in situ to Stage
IIIA breast cancer between 1996–1999. In WA, we
recruited 202 women, aged 40–64 years, diagnosed with
Stage 0-Stage IIIA breast cancer between 1997–1998. In
CA, we recruited 366 Black women aged 35–64 years,
with Stage 0-Stage IIIA breast cancer, who had partici-
pated in the Los Angeles portion of the Women’s Contra-
ceptive and Reproductive Experiences Study, diagnosed
with breast cancer between 1995–1998. Recruitment
was restricted in WA and CA to women aged 35–64 at
diagnosis because of competing studies and parent study
design. The study was performed with the approval of
the Institutional Review Boards of participating cen-
ters, in accordance with an assurance filed with and ap-
proved by the U.S. Department of Health and Human
Services. Written informed consent was obtained from
each subject.
944 women completed in-person interviews approxi-
mately 30-months following their first interview; 726
women were genotyped; we excluded 169 women with
a diagnosis of Stage 0 (in situ) disease, and 24 women
with non-fatal breast cancer events <9 months before
their 24-month interview dates to avoid potential con-
founding from possible recent treatment. The final sam-
ple size is 533.
Data collection and covariates
Specimens
DNA was extracted from peripheral blood leukocytes,
which was processed within 3 hours of collection, and
stored at -80º C until analysis (Abrahamson et al. 2007).
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GSTT1, GSTP1 and GSTM1 were genotyped at Albany
Molecular Research in Bothell, Washington. The presence/
absence of the GSTM1 and GSTT1 alleles were detected
by PCR, and the Taqman allelic discrimination method
(Applied Biosystems, Foster City, CA) was used to differen-
tiate GSTP1 genotypes (Kelada et al. 2003). We included
10% replica samples and genotype concordance was 100%.
The GSTM1 and GSTT1 mutations were classified as GST
null or GST positive genotypes.
Covariates and inflammatory biomarkers
Standardized questionnaire information including med-
ical history, demographic and lifestyle information, was
collected at approximately 6- and 30-months post-
diagnosis. With participants wearing light indoor cloth-
ing and no shoes, weight was measured to the nearest 0.1
kg, and height to the nearest 0.1 cm. All measurements
were performed twice, and averaged. Body mass index
(BMI) was calculated as kg/m2. A race/ethnicity/study
site 4-category variable was created to adjust for race and
site-associated confounding as these were highly corre-
lated. The variable had 4 categories: Non-Hispanic whites
(NM); non-Hispanic whites (WA); Hispanics; and African
Americans.
Serum levels of C-reactive protein (CRP) were mea-
sured as described previously (Pierce et al. 2009b). CRP
was non-normally distributed and was log-transformed.
Stage of disease and cancer treatment
Participants were classified as having Stage 0 (in situ),
Stage I (localized) or Stage II-IIIA (regional) breast cancer
based on AJCC stage of disease classification contained
within SEER. This analysis includes only women with
Stage I-IIIa at diagnosis because few deaths occurred in
women with Stage 0 disease. Estrogen receptor (ER)
status was categorized as positive, negative, or unknown/
borderline. Treatment and additional clinical data were
obtained from medical record reviews. Treatment was
categorized into 3 groups: surgery only, surgery plus radi-
ation, or surgery with any chemotherapy with or without
radiation.
Outcome assessment
Information on vital status and cause of death codes
were acquired from linkages with SEER databases. If
alive, individuals were followed through their last follow-
up assessment or SEER vital status update, whichever
was most recent. All-cause mortality was defined as time
from study enrollment to death from any cause, or end of
follow-up (31 December 2009). Breast cancer-specific
mortality was defined as death from breast cancer or
end of follow-up, with the same intervals as for all-cause
mortality.Statistical analysis
Differences in distribution of continuous variables be-
tween genotypes were estimated using analysis of variance
(ANOVA). Differences in distributions of categorical vari-
ables were compared using the Chi-square test. As the
numbers of patients homozygous for the GSTP1 variant al-
lele were few, heterozygous and homozygous variant allele
groups were combined (recessive model). Hazard ratios
(HR) and 95% confidence intervals (CI) for breast cancer-
specific or all-cause mortality were based on the partial
likelihood for Cox's proportional hazards model (Cox
1972). The proportional hazard assumption was tested
using Schoenfeld residuals, and no violation of the pro-
portionality assumption was found. Age was used as the
underlying time variable, with entry and exit time defined
as the participant’s age at the baseline interview, and age
at death from either breast cancer or any cause, or end of
follow-up, respectively.
We based variable inclusion on a likelihood ratio test,
with the following covariates included in models: race/
ethnicity/study-site (to adjust for different distributions
of race/ethnicity by study site); BMI (categorical <18.5
kg/m2; ≥18.5 and <25 kg/m2; ≥25 and <40 kg/m2; ≥40
kg/m2); SEER summary tumor stage (local vs. regional)
and treatment received at diagnosis (surgery; surgery+
radiotherapy; chemotherapy). Covariates considered but
not included in the final model (they did not significantly
change the likelihood ratio score): menopausal status, edu-
cation, smoking status, tamoxifen use, and ER status. The
Wald statistic was used to test for trend across levels.
We determined whether the association of GST vari-
ants with outcome was the same across subgroup cat-
egories, using a test of homogeneity of trends across
groups; specifically stage, ER status; and treatment re-
ceived. Due to small numbers of events in premenopausal
participants, we did not compare pre- and postmenopausal
subgroups.
All p-values are two-sided. Analyses were performed
using STATA 11 (Statacorp, TX USA).
Results
Mean age of participants was 57.6 years (Table 1);
more than half (52.5%) of participants carried at least
one GSTM1 null mutation, and significantly more African
American women carried it compared to NHW or
Hispanics (χ2=34.36 P<0.0001). 79.6% of participants car-
ried at least one GSTT1 null mutation; there was no
difference in the proportion of carriers and non-carriers
across racial/ethnic groups. For the GSTP1 Ile105Val poly-
morphism, 58.2% of participants carried at least one vari-
ant allele; there were no differences across racial/ethnic
groups. The GSTP1 105Ile/Val polymorphism was in
Hardy-Weinberg equilibrium (P>0.05). Median follow-up
time was 11.29 years.
Table 1 Characteristics of the HEAL cohort
Alla Non-Hispanic African American Hispanic
N(%) White N(%) N(%) N(%)
533 305 151 60
Study Site
Western Washington 99 83 0 2
New Mexico 283 222 0 58
Los Angeles 151 0 151 0
Body mass index (BMI) (kg/m2)
Mean (s.d) 27.8 (6.4) 26.5 (5.7) 30.7 (7.4) 27.1 (4.7)
Age (years)
Mean (s.d.) 57.6 (10.7) 60.6 (10.9) 52.4 (7.9) 56.2 (11.3)
Estrogen receptor (ER) status
Negative 109 43 52 13
Positive 375 237 88 36
Unknown 49 25 11 11
SEERb summary stage
Local 383 241 85 46
Regional 150 64 66 14
Treatment at diagnosis
Surgery 126 69 37 18
Surgery and radiotherapy 203 138 37 21
Any chemotherapy 204 98 77 21
GSTM1
Null Genotype 280 (52.5) 138 (45.3) 109 (72.2) 28 (46.7)
Positive Genotype 253 (47.5) 167 (54.7) 42 (27.8) 32 (53.3)
χ2 = 34.36 P<0.0001
GSTT1
Null Genotype 424 (79.6) 249 (81.6) 115 (76.2) 49 (81.7)
Positive Genotype 109 (20.4) 56 (18.4) 36 (23.8) 11 (18.3)
χ2 = 4.35 P=0.22
GSTP1
Wildtype (Ile/Ile) 223 (41.8) 137 (44.9) 53 (35.1) 27 (45.0)
Heterozygous (Ile/Val) 250 (46.9) 137 (44.9) 76 (50.3) 27 (45.0)
Homozygous (Val/Val) 60 (11.3) 31 (10.2) 22 (14.6) 6 (10.0)
χ2 = 6.16 P=0.41
a 17 patients were described as ‘other race’; this accounts for the differences in numbers between racial/ethnic subgroups and the overall total.
b Surveillance, Epidemiology and End Results (SEER).
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ticipants’ characteristics (ER, tumor stage and BMI), car-
riers of the GSTM1 null mutation were more likely to
have stage 3 tumors (χ2=3.87 P=0.05) compared to non-
carriers (Table 2). Carriers of the GSTT1 null mutation
were more likely to have ER-negative tumors (χ2=4.52;
P=0.03). There were no significant associations between
the GSTP1 polymorphism and patient characteristics.
When we excluded participants who had surgery onlyfrom the analysis, these associations were no longer
significant (P=0.06 for both) but this may be due to
smaller numbers.
Carriers of the GSTT1 null mutation had significantly
higher levels of CRP compared to non-carriers (mean:
4.54 vs. 3.01 mg/L; P=0.01). Levels were also signifi-
cantly higher in participants with diabetes (mean: 10.23
vs. 2.92 mg/L; P=0.02), but there were no differences in
participants without diabetes. In contrast the GSTM1 null
Table 2 Associations between SNPs and participant characteristics
All participants N=553
GSTM1 GSTT1 GSTP1
Positive Null Positive Null Ile/Ile Ile/Val Val/Val
BMI (kg/m2)
<=25 102 116 52 166 95 103 20
(40.3%) (41.43%) (47.7%) (39.2%) (42.6%) (41.2%) (33.3%)
>25 151 164 57 258 128 147 40
(59.7%) (58.6%) (52.2%) (60.8%) (57.4%) (58.8) (66.7%)
χ2=0.10 P =0.79 χ2=2.62 P =0.11 χ2=1.70 P =0.43
ERa
ER- 45 64 15 94 41 57 11
(19.6%) (25.2%) (14.7%) (24.6%) (19.8%) (25.6%) (20.0%)
ER+ 185 190 87 288 166 165 44
(80.4%) (74.8%) (85.3%) (75.4%) (80.2%) (74.3%) (80.0%)
χ2=2.19 P=0.14 χ2=4.52 P=0.03 χ2=2.34 P=0.31
Stage
Local 192 191 75 308 154 188 41
(75.9%) (68.2%) (68.8%) (72.6%) (67.1%) (75.2%) (68.3%)
Regional 61 89 34 116 69 62 19
(24.1%) (31.8%) (31.2%) (27.4%) (30.9%) (24.8%) (31.7%)
χ2=3.87 P=0.05 χ2=0.63 P=0.42 χ2=2.61 P=0.27
Omitting patients who received surgery only N=407
GSTM1 GSTT1 GSTP1
Positive Null Positive Null Ile/Ile Ile/Val Val/Val
BMI (kg/m2)
<=25 72 89 40 121 72 73 16
(37.1%) (41.8%) (46.5%) (37.7%) (40.9%) (39.5%) (34.8%)
>25 122 124 46 200 104 112 30
(62.9%) (58.2%) (53.5%) (62.3%) (59.1%) (60.5) (65.2%)
χ2=0.92 P =0.34 χ2=2.21 P =0.14 χ2=0.57 P =0.75
ERa
ER- 38 57 13 82 36 50 9
(20.5%) (28.6%) (15.3%) (27.4%) (21.4%) (29.1%) (20.5%)
ER+ 147 142 72 217 132 122 35
(79.5%) (71.4%) (84.7%) (72.6%) (78.6%) (70.9%) (79.6%)
χ2=3.38 P=0.06 χ2=5.23 P=0.02 χ2=3.16 P=0.21
Stage
Local 141 136 59 218 113 134 30
(72.7%) (63.9%) (68.6%) (67.9%) (64.2%) (72.4%) (65.2%)
Regional 53 77 27 103 63 51 16
(27.3%) (36.1%) (31.4%) (32.1%) (35.8%) (27.68%) (34.8%)
χ2=3.64 P=0.06 χ2=0.01 P=0.91 χ2=3.00 P=0.22
a Omitted 49 participants with unknown ER status’.
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CRP among diabetics only (mean: 4.83 vs. 14.61 mg/dL).
There were no associations between GSTP1 and CRP (data
not shown).
No significant association was observed between either
GSTM1 or GSTT1 null mutations, and breast- or all-cause
mortality. Heterozygous carriers of the GSTP1 Ile105Val
polymorphism had a significantly increased HR for all-
cause mortality, compared to wild-type homozygotes
(HR=1.98; 95% CI 1.25-3.12). When examined as a reces-
sive model (all carriers of the variant allele, vs. wild-type
homozygotes), the variant allele was associated with an in-
creased risk of all-cause mortality (HR=1.81; 95% CI 1.16-
2.82). There was no association between the GSTP1
Ile105Val polymorphism and breast cancer-specific mor-
tality. When we examined risk in women who were post-
menopausal at baseline (N=341), HR was similar to that
in the entire population for all 3 polymorphisms (data
not shown). Finally, we examined associations with mortal-
ity in patients who received any treatment (chemotherapy/
radiotherapy): there were no differences in associations for
GSTT1 and GSTM1. The association for GSTP1 for homo-
zygous Val/Val changed from HR=1.24 95% CI 0.59-2.58)
to HR=0.60 95% CI 0.20-1.75 (Table 3).
We performed a 3-way gene analysis, examining com-
binations of GSTM1 null/present; GSTT1 null/present
and GSTP1 105Ile/Ile vs. Ile/Val+Val/Val. An increased
risk of all-cause mortality was observed for each group
relative to the referent (GSTM1 present/GSTT1 present/
GSTP1 105Ile/Ile), but none reached statistical signifi-
cance (data not shown). Breast cancer-specific mortality
demonstrated a different pattern, with carriers of GSTT1
null mutation/GSTM1 present/GSTP1 105Ile/Ile geno-
types associated with a reduced risk (HR=0.12; 95% CI
0.01-1.16) compared to participants with GSTM1 present/
GSTT1 present/homozygous wild-type for GSTP1. How-
ever this association was not significant (P=0.06).
We next analyzed the same endpoints for GSTP1,
GSTM1 and GSTT1 polymorphisms in patient sub-
groups, using fully adjusted models. The GSTP1 Val allele
was associated with an approximate 2-fold increased risk
of all-cause mortality in patients with ER-positive tumors,
compared to those with ER-negative, though this was not
significant (P=0.08). There was no evidence of effect
modification for other subgroups examined. Due to lim-
ited power we did not examine associations for breast
cancer-specific mortality in these subgroups.
Discussion
There are few studies on the role of GST isoenzymes on
mortality in breast-cancer survivors drawn from com-
munity practice. As described earlier, the majority of
these studies had small sample sizes, were based on partici-
pants diagnosed prior to 1999, and on women undergoingchemotherapy and/or radiotherapy. In addition, most ex-
amined only one GST gene (usually GSTP1).
Here we report that the variant Val allele of GSTP1
(rs1695) was associated with increased risk of all-cause
mortality, but not breast cancer-specific mortality, in a
cohort of 533 breast-cancer survivors. The amino acid
substitution in GSTP1 Ile105Val, results in an enzyme
with altered activity, (Ali-Osman et al. 1997) including
towards alkylating anticancer agents, (Hayes & Strange
2000; Pandya et al. 2000; Srivastava et al. 1999) and the
decreased risk of mortality in carriers of the variant al-
lele who receive chemotherapy may be attributable to
longer exposure to the active agent in therapy. Patients
homozygous for the variant allele had a lower risk of
chemo-resistance when treated with doxorubicin (OR=
0.11; 95% CI 0.01-0.90; P=0.04) (Romero et al. 2012).
However, when we examined the association of GSTP1
polymorphisms in subgroups of patients, we found no
association between the polymorphism and treatment
received.
In contrast, deletions in the GSTM1 or GSTT1 genes
were not associated with mortality confirming results
from one other study, (Yang et al. 2005) but not in an-
other, (Ambrosone et al. 2001) though the latter studied
women recruited between mid 1980s-1990s.
We also found an association between breast cancer-
specific mortality with carriers of GSTT1 null mutation/
GSTM1 present/GSTP1 Ile/Ile genotypes associated with
a reduced risk of breast cancer-specific mortality compared
to participants with GSTM1 present/GSTT1 present/
homozygous wild-type for GSTP1. While this was not
significant, we cannot discount inadequate power.
When we examined associations in patients who re-
ceived any treatment (chemotherapy/radiotherapy; ex-
cluding those who received surgery only), homozygous
carriers of the GSTP1 Val allele had a decreased risk of
all-cause mortality, although this was not significant,
compared to all participants. This is similar to another
report in Chinese women who all received adjuvant
chemotherapy; (Yang et al. 2005) another reported that
the GSTP1 Val/Val polymorphism was non-significantly
associated with worse overall survival in women treated
with high-dose chemotherapy (Bewick et al. 2008).
We found significantly lower levels of CRP in carriers
of the GSTM1 null mutation in patients with diabetes
only; and higher levels of CRP in carriers of the GSTT1
null mutation; the latter differed from results in patients
with diabetes and smokers (lower CRP among carriers of
the GSTT1 null mutation); (Hayek et al. 2006; Miller et al.
2003) however these participants were otherwise healthy.
Limitations of our study include relatively small numbers
of events, thus we were not able to evaluate the association
with outcome by subgroups such as menopausal status;
and three-way gene analyses are underpowered. We also
Table 3 Associations between the Ile105Val polymorphisms in GSTP1, null mutations in GSTM1 and GSTT1,
and breast-cancer and all-cause mortality
Genotype Events/N total Unadjusted Full Modela Events/N total Radiotherapy+Chemotherapy only
HR 95% CI HR 95% CI HR 95% CI
Breast cancer Mortality
GSTM1
Positive genotype 17/253 1.00 Ref. 1.00 Ref. 14/194 1.00 Ref.
Null genotype 28/280 1.48 0.81-2.71 0.93 0.49-1.79 21/213 0.88 0.41-1.86
Pb 0.21 0.83 0.74
GSTT1
Positive genotype 11/109 1.00 Ref. 1.00 Ref. 8/86 1.00 Ref.
Null genotype 34/424 0.80 0.40-1.60 0.86 0.43-1.72 27/321 0.91 0.40-2.03
Pb 0.54 0.68 0.80
GSTP1
Ile/Ile 16/233 1.00 Ref. 1.00 Ref. 14/176 1.00 Ref.
Ile/Val 26/250 1.53 0.82-2.86 1.66 0.87-3.16 19/185 1.37 0.67-2.84
Val/Val 3/60 0.75 0.22-2.58 0.63 0.17-2.27 2/46 0.42 0.10-2.12
Pb 0.71 0.82 0.74
GSTP1
Ile/Ile 16/223 1.00 Ref. 1.00 Ref. 14/176 1.00 Ref.
Val/Val + Val/Ile 29/310 1.38 0.74-2.55 1.43 0.76-2.68 21/321 1.17 0.58-2.37
Pb 0.30 0.27 0.67
All cause Mortality
GSTM1
Positive genotype 45/208 1.00 Ref. 1.00 Ref. 31/194 1.00 Ref.
Null genotype 54/226 1.07 0.71-1.58 0.88 0.57-1.34 38/213 0.77 0.45-1.30
Pb 0.76 0.55 0.32
GSTT1
Positive genotype 17/109 1.00 Ref. 1.00 Ref. 12/86 1.00 Ref.
Null genotype 82/424 1.21 0.71-2.03 1.22 0.72-2.08 57/321 1.33 0.71-2.51
Pb 0.48 0.47 0.38
GSTP1
Ile/Ile 30/223 1.00 Ref. 1.00 Ref. 24/176 1.00 Ref.
Ile/Val 59/250 1.89 1.21-2.95 1.98 1.25-3.12 39/185 1.72 1.01-2.93
Val/Val 10/60 1.41 0.68-2.89 1.24 0.59-2.58 6/46 0.60 0.20-1.75
Pb 0.05 0.08 0.72
GSTP1
Ile/Ile 30/223 1.00 Ref. 1.00 Ref. 24/176 1.00 Ref.
Ile/Val + Val/Val 69/310 1.80 1.16-2.77 1.81 1.16-2.82 45/231 1.47 0.87-2.47
Pb 0.008 0.008 0.15
a Adjusted for race/ethnicity/study-site; BMI (categorical <18.5 kg/m2; ≥18.5 and <25 kg/m2; ≥25 and <40 kg/m2; ≥40 kg/m2); SEER summary tumor stage (local vs. regional)
and treatment received at diagnosis (surgery; surgery+radiotherapy; chemotherapy).
b Wald test for trend.
Boldface type indicates a statistically significant result.
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tality. The cohort was established before some current
treatments such as aromatase inhibitors and Her2/neutargeted therapies were available, and therefore we cannot
estimate what associations GST isoenzymes might have
with survival in women using these treatments. There was
Duggan et al. SpringerPlus 2013, 2:450 Page 8 of 9
http://www.springerplus.com/content/2/1/450also a possible selection bias in this study. As blood for
genotyping was obtained approximately 30-months post-
diagnosis, and we excluded participants who were under
treatment for recurrence, associations with early breast-
cancer mortality would not be observed, and it is possible
that genotype may have stronger associations closer to the
time of diagnosis.
However, our study has a larger sample size than most
prior studies examining the association between GST
polymorphisms and survival, and participants also under-
went more contemporary treatment protocols. Given the
heterogeneity of published studies (different therapies,
stages of disease, and recruitment periods), suggestions
for further study include examining larger studies of
pooled data of women diagnosed at similar time-periods
who underwent similar treatment regimens, thus enhan-
cing power to detect associations between GST isoenzymes
and longer-term survival.
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